Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3015 in Advanced Malignant Cancer
NCT06165809Phase 1Withdrawn
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3015 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at Day 21, Maximum Tolerated Dose at Day 21 and 2 more. Planned start Dec 2023; status: withdrawn.
02
Drugs
TQB3015
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06165809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165809.